VIR Vir Biotechnology

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--

Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California.

A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at and will be archived there for 30 days.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple double-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

EN
18/12/2024

Underlying

VIRVir Biotechnology

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vir Biotechnology

 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in On...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation continues, and early clinical response signals observed in heavily pretreated participants. These init...

January 8, 2025 1 EN
 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at and will be archived there for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on pow...

December 18, 2024 1 EN
 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EM...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta (CHD). The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new at AASLD The Liver Meeting® in San Diego, U.S. Vir Biotechnology’s Phase 3 ECLIPSE registrational program eval...

December 12, 2024 1 EN
 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of HER2-expressing solid tumors and VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC) along with updates on the PRO-XTEN™ platform on January 8, 2025, at 5:00 a.m. PT / 8:00 a.m. ET. A live webcast will be available on and will be archived on for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage biophar...

November 26, 2024 1 EN
 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology to Participate in the 7th Annual Evercore ISI Health...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday December 3, at 6:10 a.m. PT / 9:10 a.m. ET in Miami, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at and will be archived there for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage bi...

November 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch